Tenon Medical, Inc.

Listed Company

TNONCIK 0001560293NasdaqEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$3.94M

Net Income

$-12.56M

Total Assets

$10.76M

Equity

$5.04M

Shares Out

11.57M

Op. Cash Flow

$-10.74M

TNON$0.20−81.47% · past yearDBEQ Basic

Daily closing prices

Business

Tenon Medical, Inc. is a medical device company focused on treating sacroiliac joint disorders through minimally invasive surgical systems. The company offers The Catamaran System, which uses a single titanium implant for SI Joint fusion via an inferior-posterior approach, and The SImmetry+ System, acquired in August 2025, which employs a lateral access approach with decortication and bone grafting. Both systems target a large and underserved U.S. market for sacroiliac joint procedures. The company markets directly through independent distributors and sales representatives to spine and pelvic surgeons.

Summary from 10-K filed 2026-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	4	3	3	691,000	160,000
Cost of sales	2	2	2	1	55,000
Gross Profit	2	2	1	−641,000	105,000
General and administrative	7	8	7	7	3
Sales and marketing	6	5	7	8	2
Research and development	2	3	3	3	2
Total Operating Expenses	15	15	17	18	7
Loss from Operations	−13	−14	−16	−19	−6
Gain on investments	236,000	183,000	167,000	180,000	2,000
Interest expense	—	−34,000	−21,000	—	—
Other expense, net	—	−56,000	—	−18,000	—
Total Other Income, net	236,000	93,000	146,000	−192,000	−620,000
Net Loss	−13	−14	−16	−19	−7
Basic (in Dollars per share)	−1.7	−11.26	−68.64	−23.62	−7.81
Diluted (in Dollars per share)	−1.7	−11.26	−68.64	−23.62	−7.81
Basic (in Shares)	7,384	1,214	227	801	903
Diluted (in Shares)	7,384	1,214	227	801	903
Foreign currency translation adjustment	—	46,000	38,000	7,000	—
Total Comprehensive Loss	−13	−14	−16	−19	−7

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	4	7	2	2	3
Accounts receivable, net	2	863,000	518,000	228,000	76,000
Inventory	1	606,000	554,000	415,000	188,000
Prepaid expenses and other current assets	260,000	206,000	389,000	—	—
Total current assets	7	8	4	9	8
Property and equipment, net	918,000	752,000	961,000	793,000	101,000
Deposits	51,000	51,000	51,000	51,000	41,000
Operating lease right-of-use asset	131,000	399,000	646,000	873,000	1
Deferred offering costs	—	431,000	798,000	25,000	374,000
Intangible assets, net (Notes 3 and 6)	485,000	—	—	—	—
Goodwill (Note 3)	2	—	—	—	—
TOTAL ASSETS	11	10	6	11	9
Accounts payable	845,000	369,000	433,000	550,000	478,000
Accrued expenses	2	910,000	808,000	717,000	1
Current portion of accrued commissions	590,000	303,000	470,000	—	—
Current portion of operating lease liability	141,000	287,000	256,000	228,000	202,000
Total current liabilities	3	2	3	3	15
Accrued commissions, net of current portion	2	2	2	2	—
Operating lease liability, net of current portion	—	141,000	428,000	683,000	911,000
Contingent consideration (Note 3)	993,000	—	—	—	—
Total liabilities	6	4	6	5	16
Commitments and contingencies (Note 10)	—	—	—	—	—
Common stock, $0.001 par value; 130,000,000 shares authorized at December 31, 2025 and 2024; 10,851,273 and 3,138,804 shares issued and outstanding at December 31, 2025 and 2024, respectively	11,000	3,000	—	1,000	1,000
Additional paid-in capital	83	71	56	46	113,000
Accumulated deficit	−81	−69	−55	−39	−21
Total stockholders equity	5	6	778,000	6	−21
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	11	10	6	11	9

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	2	4	4	3	377,000
Depreciation and amortization	262,000	408,000	199,000	—	—
Provision for losses on accounts receivable	16,000	41,000	—	—	—
Amortization of operating right-of-use asset	268,000	247,000	227,000	211,000	112,000
Accounts receivable	−851,000	−386,000	−290,000	−152,000	−61,000
Inventory	−387,000	−52,000	−139,000	−227,000	−145,000
Prepaid expenses and other assets	−35,000	183,000	−301,000	−57,000	−130,000
Accounts payable	486,000	−64,000	−117,000	72,000	444,000
Accrued expenses	648,000	−171,000	−99,000	2	426,000
Operating lease liability	−287,000	−256,000	−227,000	−202,000	−82,000
Net cash used in operating activities	−11	−10	−12	−12	−4
Purchase of assets from SiVantage, Inc.	−750,000	—	—	—	—
Purchases of property and equipment	−273,000	−186,000	−361,000	−847,000	−102,000
Net cash used in investing activities	−1	−186,000	6	−3	−5
Gross proceeds from issuance of common stock, prefunded warrants, and warrants	4	5	—	—	—
Gross proceeds from exercise of warrants under inducement agreement	3	5	—	—	—
Gross proceeds from issuance of common stock and warrants	3	—	—	—	—
Gross proceeds from issuance of Series A convertible preferred stock	—	3	—	—	—
Gross proceeds from issuance of Series B convertible preferred stock	—	550,000	—	—	—
Gross proceeds from issuance of common stock	—	2	495,000	14	0
Gross proceeds from exercise of warrants	—	812,000	258,000	—	—
Offering costs	−928,000	−1	—	—	—
Net cash provided by financing activities	9	14	6	14	11
Effect of foreign currency translation on cash flow	—	46,000	38,000	7,000	−2,000
Net (Decrease) Increase in Cash and Cash Equivalents	−3	4	299,000	−788,000	3
Warrant modification costs	5	992,000	—	—	—
Preferred stock issued upon conversion of debt and accrued interest	—	1	—	14	—
Reclassification of deferred offering costs to additional paid-in capital	421,000	367,000	—	—	—
Common stock issued upon conversion of Series A preferred stock	678,000	—	—	—	—
Common stock issued for purchase of assets from SiVantage, Inc.	1	—	—	—	—
Contingent consideration for purchase of assets from SiVantage, Inc.	1	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Tenon Medical, Inc.'s CIK number?

Tenon Medical, Inc.'s SEC CIK number is 0001560293 (1560293). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Tenon Medical, Inc.'s SEC filings?

All of Tenon Medical, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Tenon Medical, Inc. last report earnings?

Tenon Medical, Inc. (TNON) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-055085). This is Tenon Medical, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Tenon Medical, Inc.'s most recent earnings 8-K?

Tenon Medical, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001213900-26-055085. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Tenon Medical, Inc.'s latest earnings 8-K →
Look up any company's CIK number →